What does ArriVent BioPharma, Inc. do?
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in…
What is ArriVent BioPharma, Inc.'s P/E and P/B ratio?
ArriVent BioPharma, Inc. has a P/E ratio of -5.3 and a P/B ratio of 2.58.
What is ArriVent BioPharma, Inc.'s debt-to-equity ratio?
ArriVent BioPharma, Inc. has a debt-to-equity ratio of 0.00.
How much does ArriVent BioPharma, Inc. owe compared with what it owns?
ArriVent BioPharma, Inc. owes $0.07 for every $1 it owns (balance sheet Jun 2026), which is low.
What is ArriVent BioPharma, Inc.'s Positivity rank?
ArriVent BioPharma, Inc. is ranked #3,933 of 6,774 companies globally and #1,840 of 4,000 in United States on PositoAI, with a Positivity Score of 20,086.
Does ArriVent BioPharma, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
No active red flags (PosiRed) or yellow flags (PosiYellow) are currently on record for ArriVent BioPharma, Inc..
Where can I read the latest news about ArriVent BioPharma, Inc.?
Recent headlines about ArriVent BioPharma, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does ArriVent BioPharma, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of ArriVent BioPharma, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.